Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: Could it be the first step of the treatment?

Roberto Caporali, Serena Bugatti, Lorenzo Cavagna, Marco Antivalle, Piercarlo Sarzi-Puttini

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Advances in our understanding of the key mediators of chronic inflammation and tissue damage in rheumatoid arthritis (RA) have fostered the development of targeted therapies and greatly expanded the available treatment options. Abatacept, a soluble human fusion protein that selectively modulates the co-stimulatory signal required for full T-cell activation, is approved for the treatment of moderate to severe RA in the United States, Canada, and the European Union. This review summarises the data on efficacy (disease activity, quality of life, prevention of structural damage) and safety from randomised clinical trials of abatacept plus methotrexate in patients with: i) active RA and an inadequate response to methotrexate who are naïve to biological disease-modifying anti-rheumatic drugs; and ii) methotrexate-naïve early RA with poor prognostic factors. Novel imaging outcomes and biological changes induced by abatacept treatment are also briefly reviewed. Optimal use of abatacept as a first-line biological therapy is discussed in light of the current recommendations and guidelines.

Original languageEnglish
Pages (from-to)49-53
Number of pages5
JournalAutoimmunity Reviews
Volume13
Issue number1
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Rheumatoid Arthritis
Methotrexate
T-Lymphocytes
Inflammation Mediators
Biological Therapy
Antirheumatic Agents
European Union
Therapeutics
Canada
Randomized Controlled Trials
Quality of Life
Guidelines
Safety
Abatacept
Proteins

Keywords

  • Abatacept
  • Rheumatoid arthritis
  • T cells

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis : Could it be the first step of the treatment? / Caporali, Roberto; Bugatti, Serena; Cavagna, Lorenzo; Antivalle, Marco; Sarzi-Puttini, Piercarlo.

In: Autoimmunity Reviews, Vol. 13, No. 1, 01.2014, p. 49-53.

Research output: Contribution to journalArticle

@article{a5a4b3320a404e42b6ffaeb705ce2c48,
title = "Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: Could it be the first step of the treatment?",
abstract = "Advances in our understanding of the key mediators of chronic inflammation and tissue damage in rheumatoid arthritis (RA) have fostered the development of targeted therapies and greatly expanded the available treatment options. Abatacept, a soluble human fusion protein that selectively modulates the co-stimulatory signal required for full T-cell activation, is approved for the treatment of moderate to severe RA in the United States, Canada, and the European Union. This review summarises the data on efficacy (disease activity, quality of life, prevention of structural damage) and safety from randomised clinical trials of abatacept plus methotrexate in patients with: i) active RA and an inadequate response to methotrexate who are na{\"i}ve to biological disease-modifying anti-rheumatic drugs; and ii) methotrexate-na{\"i}ve early RA with poor prognostic factors. Novel imaging outcomes and biological changes induced by abatacept treatment are also briefly reviewed. Optimal use of abatacept as a first-line biological therapy is discussed in light of the current recommendations and guidelines.",
keywords = "Abatacept, Rheumatoid arthritis, T cells",
author = "Roberto Caporali and Serena Bugatti and Lorenzo Cavagna and Marco Antivalle and Piercarlo Sarzi-Puttini",
year = "2014",
month = "1",
doi = "10.1016/j.autrev.2013.06.008",
language = "English",
volume = "13",
pages = "49--53",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis

T2 - Could it be the first step of the treatment?

AU - Caporali, Roberto

AU - Bugatti, Serena

AU - Cavagna, Lorenzo

AU - Antivalle, Marco

AU - Sarzi-Puttini, Piercarlo

PY - 2014/1

Y1 - 2014/1

N2 - Advances in our understanding of the key mediators of chronic inflammation and tissue damage in rheumatoid arthritis (RA) have fostered the development of targeted therapies and greatly expanded the available treatment options. Abatacept, a soluble human fusion protein that selectively modulates the co-stimulatory signal required for full T-cell activation, is approved for the treatment of moderate to severe RA in the United States, Canada, and the European Union. This review summarises the data on efficacy (disease activity, quality of life, prevention of structural damage) and safety from randomised clinical trials of abatacept plus methotrexate in patients with: i) active RA and an inadequate response to methotrexate who are naïve to biological disease-modifying anti-rheumatic drugs; and ii) methotrexate-naïve early RA with poor prognostic factors. Novel imaging outcomes and biological changes induced by abatacept treatment are also briefly reviewed. Optimal use of abatacept as a first-line biological therapy is discussed in light of the current recommendations and guidelines.

AB - Advances in our understanding of the key mediators of chronic inflammation and tissue damage in rheumatoid arthritis (RA) have fostered the development of targeted therapies and greatly expanded the available treatment options. Abatacept, a soluble human fusion protein that selectively modulates the co-stimulatory signal required for full T-cell activation, is approved for the treatment of moderate to severe RA in the United States, Canada, and the European Union. This review summarises the data on efficacy (disease activity, quality of life, prevention of structural damage) and safety from randomised clinical trials of abatacept plus methotrexate in patients with: i) active RA and an inadequate response to methotrexate who are naïve to biological disease-modifying anti-rheumatic drugs; and ii) methotrexate-naïve early RA with poor prognostic factors. Novel imaging outcomes and biological changes induced by abatacept treatment are also briefly reviewed. Optimal use of abatacept as a first-line biological therapy is discussed in light of the current recommendations and guidelines.

KW - Abatacept

KW - Rheumatoid arthritis

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=84886952210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886952210&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2013.06.008

DO - 10.1016/j.autrev.2013.06.008

M3 - Article

C2 - 23777823

AN - SCOPUS:84886952210

VL - 13

SP - 49

EP - 53

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 1

ER -